Introduction
Methods
Participants
Study outcomes: mortality
Study exposure: sleep duration
Covariates
Statistical analysis
Results
Participant characteristics
Characteristic | Sleep duration (h/day) | |||||
---|---|---|---|---|---|---|
≤5 | 6 | 7 | 8 | 9 | ≥10 | |
Sample size, n (%) | 2957 (12.2) | 5054 (20.9) | 5379 (22.2) | 7497 (31.0) | 1341 (5.5) | 1984 (8.2) |
Mean age, years | 59.1 | 59.8 | 60.4 | 62.9 | 65.9 | 66.3 |
Sex, n (%) | ||||||
Male | 1179 (43.9) | 2238 (49.0) | 2538 (51.9) | 3535 (51.4) | 601 (48.3) | 888 (48.8) |
Female | 1778 (56.1) | 2816 (51.1) | 2841 (48.2) | 3962 (48.6) | 740 (51.7) | 1096 (51.2) |
Race, n (%) | ||||||
Hispanic | 572 (14.7) | 895 (14.0) | 987 (14.2) | 1416 (14.6) | 182 (10.5) | 313 (12.5) |
Non-Hispanic white | 1464 (60.2) | 2684 (62.9) | 3049 (65.8) | 4201 (65.4) | 859 (73.4) | 1143 (68.2) |
Non-Hispanic black | 756 (20.1) | 1143 (16.7) | 1014 (13.9) | 1509 (14.7) | 238 (12.0) | 440 (15.3) |
Non-Hispanic other | 165 (5.0) | 332 (6.5) | 329 (6.1) | 371 (5.3) | 62 (4.1) | 88 (4.0) |
Education level, n (%) | ||||||
Less than high school degree | 894 (26.7) | 1248 (21.7) | 1204 (18.5) | 2104 (24.6) | 377 (24.8) | 752 (35.4) |
High school degree | 865 (30.6) | 1491 (30.8) | 1580 (30.8) | 2310 (32.0) | 429 (32.9) | 582 (31.8) |
More than high school degree | 1180 (42.1) | 2291 (47.2) | 2577 (50.4) | 3037 (42.8) | 529 (41.9) | 629 (32.0) |
Household income, n (%) | ||||||
Low | 873 (23.8) | 1002 (14.3) | 857 (11.6) | 1414 (13.9) | 250 (13.5) | 497 (18.9) |
Middle | 1604 (55.6) | 2778 (55.7) | 2843 (50.5) | 4320 (57.4) | 799 (59.8) | 1211 (62.7) |
High | 480 (20.6) | 1274 (30.1) | 1679 (37.9) | 1763 (28.8) | 292 (26.7) | 276 (18.4) |
BMI, n (%) | ||||||
Normal weight/underweight (<25 kg/m2) | 412 (12.8) | 721 (13.0) | 779 (13.6) | 1269 (16.3) | 252 (17.7) | 376 (18.9) |
Pre-obese (25–30 kg/m2) | 786 (26.1) | 1463 (27.8) | 1721 (32.0) | 2421 (32.7) | 431 (32.3) | 561 (27.6) |
Obese (>30 kg/m2) | 1668 (58.4) | 2741 (56.2) | 2737 (51.5) | 3561 (47.8) | 630 (47.6) | 994 (51.1) |
Meeting physical activity requirements, n (%) | 686 (23.6) | 1409 (29.6) | 1738 (35.0) | 2158 (29.9) | 349 (27.7) | 287 (15.0) |
Smoking status, n (%) | ||||||
Never | 1425 (47.0) | 2559 (48.7) | 2850 (51.7) | 3868 (50.9) | 627 (45.4) | 908 (44.8) |
Previous | 852 (28.9) | 1635 (34.1) | 1753 (33.2) | 2590 (35.3) | 510 (40.2) | 739 (39.3) |
Current | 677 (24.0) | 850 (17.1) | 769 (14.7) | 1028 (13.7) | 299 (14.1) | 334 (15.8) |
Alcohol drinking status, n (%) | ||||||
Never | 865 (27.0) | 1394 (25.3) | 1484 (24.7) | 2207 (27.6) | 388 (26.0) | 617 (29.3) |
Previous | 905 (30.3) | 1454 (28.5) | 1431 (25.1) | 2247 (29.6) | 452 (32.6) | 776 (38.1) |
Current | 1162 (41.6) | 2171 (45.7) | 2415 (49.3) | 2986 (41.9) | 498 (41.3) | 581 (32.2) |
Hypertension, n (%) | 2238 (72.9) | 3720 (71.7) | 3746 (67.5) | 5353 (69.6) | 1014 (74.4) | 1549 (76.1) |
CHD, n (%) | 524 (18.2) | 821 (15.0) | 730 (13.4) | 1279 (17.3) | 273 (20.9) | 464 (24.2) |
Stroke, n (%) | 312 (10.0) | 418 (7.5) | 358 (5.8) | 706 (9.2) | 183 (13.7) | 362 (18.9) |
Cancer, n (%) | 454 (15.5) | 713 (14.3) | 784 (14.0) | 1109 (14.6) | 248 (19.2) | 381 (20.3) |
Diabetes duration, n (%) | ||||||
0–5 years | 998 (37.3) | 1686 (35.1) | 1898 (37.7) | 2407 (33.5) | 388 (29.6) | 488 (25.9) |
6 – ≤10 years | 671 (22.5) | 1165 (23.3) | 1264 (24.2) | 1703 (23.0) | 286 (22.5) | 407 (21.1) |
11 – ≤20 years | 798 (26.0) | 1328 (25.4) | 1380 (24.8) | 1965 (25.9) | 363 (26.1) | 561 (28.3) |
>20 years | 490 (14.2) | 872 (16.3) | 837 (13.3) | 1422 (17.6) | 304 (21.8) | 528 (24.8) |
Age at diabetes diagnosis, n (%) | ||||||
0–45 years | 1217 (42.3) | 2016 (43.0) | 1937 (37.4) | 2518 (35.2) | 414 (31.0) | 658 (34.9) |
>45 years | 1740 (57.7) | 3038 (57.0) | 3442 (62.6) | 4979 (64.8) | 927 (69.1) | 1326 (65.2) |
Impact of sleep duration on mortality
Sleep duration, h/day | Participants, n | Deaths, n | Age-standardised mortality rate (per 10,000 person-years) | Model 1a | Model 2b | ||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
No diabetes | |||||||
≤5 | 20,676 | 1563 | 122.2 | 1.74 (1.48, 1.79) | <0.001 | 1.33 (1.13, 1.56) | 0.001 |
6 | 52,316 | 2788 | 91.2 | 1.27 (1.11, 1.46) | <0.001 | 1.13 (0.99, 1.29) | 0.08 |
7 | 75,182 | 3659 | 78.3 | 1 (reference) | – | 1 (reference) | – |
8 | 79,669 | 5793 | 103.6 | 1.36 (1.21, 1.53) | <0.001 | 1.26 (1.12, 1.41) | <0.001 |
9 | 11,313 | 1281 | 133.8 | 1.65 (1.36, 1.99) | <0.001 | 1.45 (1.20, 1.75) | <0.001 |
≥10 | 9661 | 1976 | 255.5 | 2.72 (2.32, 3.20) | <0.001 | 1.90 (1.62, 2.23) | <0.001 |
Type 2 diabetes | |||||||
≤5 | 2957 | 521 | 215.0 | 2.78 (2.14, 3.61) | <0.001 | 1.63 (1.24, 2.13) | <0.001 |
6 | 5054 | 806 | 176.8 | 2.37 (1.93, 2.93) | <0.001 | 1.59 (1.29, 1.95) | <0.001 |
7 | 5379 | 779 | 138.0 | 1.84 (1.51, 2.34) | <0.001 | 1.42 (1.16, 1.73) | 0.001 |
8 | 7497 | 1468 | 169.4 | 2.20 (1.87, 2.58) | <0.001 | 1.56 (1.33, 1.84) | <0.001 |
9 | 1341 | 348 | 224.2 | 2.58 (1.90, 3.51) | <0.001 | 1.74 (1.27, 2.38) | 0.001 |
≥10 | 1984 | 671 | 363.5 | 3.67 (2.93, 4.60) | <0.001 | 2.17 (1.72, 2.73) | <0.001 |
Cause of mortality | Participants, n | Deaths, n | Mortality risk according to sleep duration, HR (95% CI) | p trend | p interactiona | |||||
---|---|---|---|---|---|---|---|---|---|---|
≤5 h/day | 6 h/day | 7 h/day | 8 h/day | 9 h/day | ≥10 h/day | |||||
All-cause mortality | ||||||||||
Total | 24,212 | 4593 | 1.24 (1.09, 1.40) | 1.13 (1.01, 1.28) | 1 (reference) | 1.17 (1.06, 1.30) | 1.33 (0.98, 1.50) | 1.83 (1.61, 2.08) | <0.001 | |
Women | 13,233 | 2331 | 1.14 (0.96, 1.36) | 1.11 (0.94, 1.31) | 1 (reference) | 1.14 (0.99, 1.31) | 1.23 (0.99, 1.53) | 1.70 (1.45, 1.99) | <0.001 | 0.87 |
Men | 10,979 | 2262 | 1.33 (1.10, 1.61) | 1.21 (0.83, 1.76) | 1 (reference) | 1.18 (1.02, 1.38) | 1.43 (1.15, 1.78) | 1.93 (1.60, 2.34) | <0.001 | |
CVD mortality | ||||||||||
Total | 24,212 | 975 | 1.20 (0.90, 1.61) | 1.14 (0.89, 1.46) | 1 (reference) | 1.16 (0.93, 1.46) | 1.36 (0.95, 1.93) | 1.74 (1.33, 2.28) | 0.005 | |
Women | 13,233 | 456 | 0.86 (0.57, 1.30) | 0.96 (0.67, 1.37) | 1 (reference) | 0.94 (0.69, 1.28) | 1.08 (0.65, 1.80) | 1.42 (0.99, 2.04) | 0.03 | 0.41 |
Men | 10,979 | 519 | 1.57 (1.03, 2.40) | 1.33 (0.93, 1.90) | 1 (reference) | 1.36 (0.96, 1.93) | 1.64 (0.99, 2.73) | 2.05 (1.39, 3.02) | 0.08 | |
Cancer mortality | ||||||||||
Total | 24,212 | 995 | 1.41 (1.07, 1.86) | 1.14 (0.88, 1.48) | 1 (reference) | 1.26 (1.02, 1.56) | 1.23 (0.87, 1.71) | 1.59 (1.19, 2.21) | 0.21 | |
Women | 13,233 | 478 | 1.31 (0.86, 1.98) | 1.07 (0.73, 1.56) | 1 (reference) | 1.29 (0.94, 1.76) | 1.02 (0.61, 1.70) | 1.48 (0.97, 2.25) | 0.43 | 0.85 |
Men | 10,979 | 517 | 1.51 (1.04, 2.19) | 1.21 (0.83, 1.76) | 1 (reference) | 1.22 (0.91, 1.62) | 1.41 (0.88, 2.27) | 1.77 (1.17, 2.69) | 0.30 | |
Heart disease mortality | ||||||||||
Total | 24,212 | 779 | 1.13 (0.81, 1.58) | 1.03 (0.77, 1.38) | 1 (reference) | 1.10 (0.85, 1.43) | 1.29 (0.88, 1.90) | 1.51 (1.11, 2.07) | 0.034 | |
Women | 13,233 | 340 | 0.74 (0.45, 1.20) | 0.88 (0.57, 1.35) | 1 (reference) | 0.88 (0.62, 1.26) | 1.06 (0.59, 1.91) | 1.16 (0.72, 1.86) | 0.11 | 0.49 |
Men | 10,979 | 439 | 1.48 (0.94, 2.33) | 1.17 (0.78, 1.74) | 1 (reference) | 1.25 (0.86, 1.83) | 1.46 (0.85, 2.49) | 1.79 (1.18, 2.73) | 0.17 | |
Stroke mortality | ||||||||||
Total | 24,212 | 196 | 1.64 (0.83, 3.24) | 1.79 (0.99, 3.23) | 1 (reference) | 1.50 (0.88, 2.58) | 1.76 (0.77, 4.04) | 2.95 (1.63, 5.34) | 0.07 | |
Women | 13,233 | 116 | 1.37 (0.60, 3.11) | 1.20 (0.60, 2.42) | 1 (reference) | 1.16 (0.60, 2.25) | 1.06 (0.59, 1.91) | 2.21 (1.06, 4.59) | 0.24 | 0.66 |
Men | 10,979 | 80 | 2.78 (0.77, 10.08) | 3.27 (1.02, 10.48) | 1 (reference) | 2.61 (0.88, 7.72) | 1.46 (0.85, 2.49) | 5.21 (1.80, 15.10) | 0.16 | |
Influenza and pneumonia mortality | ||||||||||
Total | 24,212 | 88 | 1.11 (0.46, 2.67) | 0.49 (0.18, 1.31) | 1 (reference) | 1.35 (0.64, 2.84) | 0.86 (0.34, 2.17) | 1.30 (0.58, 2.90) | 0.23 | |
Women | 13,233 | 49 | 1.95 (0.52, 5.20) | 1.05 (0.30, 3.67) | 1 (reference) | 2.08 (0.78, 5.58) | 1.80 (0.52, 6.22) | 1.75 (0.66, 4.63) | 0.44 | 0.46 |
Men | 10,979 | 39 | 0.86 (0.22, 3.31) | 0.22 (0.05, 0.97) | 1 (reference) | 0.98 (0.37, 2.63) | 0.28 (0.06, 1.46) | 0.88 (0.25, 3.09) | 0.51 | |
Kidney disease mortality | ||||||||||
Total | 24,212 | 135 | 2.20 (1.00, 4.84) | 1.57 (0.59, 4.19) | 1 (reference) | 1.17 (0.59, 2.33) | 3.15 (1.26, 7.85) | 5.18 (2.18, 12.28) | 0.05 | |
Women | 13,233 | 69 | 2.26 (0.89, 5.75) | 1.77 (0.54, 5.80) | 1 (reference) | 0.94 (0.38, 2.29) | 3.74 (1.33, 10.49) | 3.12 (0.99, 9.79) | 0.63 | 0.37 |
Men | 10,979 | 66 | 2.40 (0.73, 7.83) | 1.20 (0.44, 3.28) | 1 (reference) | 1.44 (0.62, 3.37) | 2.25 (0.53, 9.50) | 8.16 (2.93, 22.87) | 0.009 | |
Alzheimer’s disease mortality | ||||||||||
Total | 24,212 | 74 | 0.90 (0.34, 2.42) | 0.79 (0.34, 1.86) | 1 (reference) | 0.87 (0.40, 1.91) | 1.34 (0.47, 3.85) | 2.64 (1.14, 6.08) | 0.013 | |
Women | 13,233 | 49 | 0.53 (0.13, 1.64) | 1.59 (0.64, 3.93) | 1 (reference) | 1.04 (0.37, 2.89) | 2.24 (0.75, 6.64) | 2.97 (1.15, 7.68) | 0.028 | 0.30 |
Men | 10,979 | 25 | 0.86 (0.26, 2.80) | 0.15 (0.01, 1.96) | 1 (reference) | 0.59 (0.16, 2.22) | 0.45 (0.05, 3.99) | 1.80 (0.45, 7.25) | 0.10 | |
CLRD mortality | ||||||||||
Total | 24,212 | 202 | 1.21 (0.61, 2.41) | 1.42 (0.82, 2.46) | 1 (reference) | 1.83 (1.08, 3.08) | 1.41 (0.69, 2.91) | 2.55 (1.42, 4.60) | 0.014 | |
Women | 13,233 | 109 | 0.63 (0.24, 1.46) | 1.18 (0.58, 2.38) | 1 (reference) | 1.77 (0.88, 3.55) | 1.10 (0.39, 3.14) | 2.55 (1.42, 4.60) | 0.002 | 0.50 |
Men | 10,979 | 93 | 2.20 (0.84, 5.75) | 1.73 (0.72, 4.17) | 1 (reference) | 1.94 (0.89, 4.24) | 1.77 (0.65, 4.84) | 2.62 (0.99, 6.90) | 0.52 |
Sleep duration and cause-specific mortality
Subgroup analyses
Cause of mortality | Mortality risk according to sleep duration, HR (95% CI) | p trend | p interactiona | |||||
---|---|---|---|---|---|---|---|---|
≤5 h/day | 6 h/day | 7 h/day | 8 h/day | 9 h/day | ≥10 h/day | |||
All-cause mortality | ||||||||
Age at diagnosis, years | ||||||||
≤45 | 1.37 (1.05, 1.79) | 1.35 (1.06, 1.73) | 1 (reference) | 1.21 (0.95, 1.53) | 1.78 (1.33, 2.37) | 2.08 (1.61, 2.71) | 0.007 | <0.001 |
>45 | 1.19 (1.02, 1.38) | 1.05 (0.92, 1.21) | 1 (reference) | 1.15 (1.03, 1.29) | 1.21 (1.02, 1.43) | 1.73 (1.50, 2.00) | <0.001 | |
Diabetes duration, years | ||||||||
≤5 | 1.08 (0.85, 1.38) | 1.17 (0.92, 1.48) | 1 (reference) | 1.08 (0.89, 1.31) | 0.94 (0.69, 1.35) | 1.68 (1.30, 2.18) | 0.08 | <0.001 |
6–10 | 1.28 (0.95, 1.72) | 1.11 (0.85, 1.44) | 1 (reference) | 1.17 (0.93, 1.47) | 1.47 (1.04, 2.10) | 1.54 (1.14, 2.08) | 0.05 | |
11–20 | 1.23 (0.95, 1.60) | 1.01 (0.80, 1.27) | 1 (reference) | 1.19 (0.94, 1.43) | 1.19 (0.89, 1.59) | 2.18 (1.73, 2.74) | <0.001 | |
>20 | 1.41 (1.08, 1.84) | 1.25 (0.98, 1.58) | 1 (reference) | 1.24 (1.00, 1.55) | 1.72 (1.30, 2.27) | 1.88 (1.49, 2.37) | 0.001 | |
CVD mortality | ||||||||
Age at diagnosis, years | ||||||||
≤45 | 1.72 (0.97, 3.05) | 1.29 (0.74, 2.25) | 1 (reference) | 1.31 (0.79, 2.15) | 1.73 (0.89, 3.37) | 1.58 (0.87, 2.86) | 0.96 | 0.222 |
>45 | 1.00 (0.70, 1.41) | 1.07 (0.81, 1.43) | 1 (reference) | 1.10 (0.86, 1.41) | 1.23 (0.82, 1.86) | 1.73 (1.28, 2.33) | 0.002 | |
Diabetes duration, years | ||||||||
≤5 | 0.75 (0.40, 1.40) | 1.44 (0.89, 2.35) | 1 (reference) | 1.25 (0.79, 1.98) | 1.61 (0.78, 3.34) | 1.23 (0.65, 2.32) | 0.26 | 0.054 |
6–10 | 0.58 (0.29, 1.15) | 0.61 (0.35, 1.08) | 1 (reference) | 0.74 (0.44, 1.25) | 1.05 (0.45, 2.47) | 0.91 (0.48, 1.71) | 0.12 | |
11–20 | 1.76 (0.98, 3.16) | 1.36 (0.84, 2.21) | 1 (reference) | 1.34 (0.84, 2.13) | 1.17 (0.59, 2.32) | 2.98 (1.80, 4.95) | 0.049 | |
>20 | 1.97 (1.08, 3.56) | 1.27 (0.75, 2.12) | 1 (reference) | 1.40 (0.89, 2.19) | 1.54 (0.85, 2.80) | 1.98 (1.24, 3.17) | 0.44 |
Cause of mortality | Mortality risk according to sleep duration, HR (95% CI) | p trend | p interactiona | |||||
---|---|---|---|---|---|---|---|---|
≤5 h/day | 6 h/day | 7 h/day | 8 h/day | 9 h/day | ≥10 h/day | |||
All-cause mortality | ||||||||
Oral glucose-lowering medication only | 1.22 (1.03, 1.44) | 1.08 (0.92, 1.27) | 1 (reference) | 1.14 (1.00, 1.29) | 1.26 (1.03, 1.55) | 1.70 (1.44, 2.02) | 0.09 | <0.001 |
Insulin only | 1.03 (0.71, 1.49) | 1.01 (0.75, 1.35) | 1 (reference) | 1.01 (0.77, 1.32) | 1.28 (0.89, 1.85) | 1.54 (1.15, 2.05) | 0.053 | |
Both oral glucose-lowering medication and insulin | 1.55 (1.09, 2.20) | 1.20 (0.87, 1.66) | 1 (reference) | 1.28 (0.96, 1.71) | 1.56 (1.07, 2.26) | 1.80 (1.32, 2.45) | <0.001 | |
No medication | 1.08 (0.72, 1.63) | 1.34 (0.93, 1.92) | 1 (reference) | 1.26 (0.94, 1.70) | 1.22 (0.72, 2.08) | 2.24 (1.49, 3.36) | 0.001 | |
CVD mortality | ||||||||
Oral glucose-lowering medication only | 0.97 (0.67, 1.41) | 0.96 (0.69, 1.33) | 1 (reference) | 0.93 (0.70, 1.23) | 1.10 (0.67, 1.80) | 1.38 (0.96, 1.98) | 0.26 | 0.001 |
Insulin only | 1.04 (0.44, 2.43) | 1.67 (0.88, 3.18) | 1 (reference) | 1.08 (0.09, 1.96) | 1.68 (0.79, 3.58) | 1.99 (1.01, 3.91) | 0.12 | |
Both oral glucose-lowering medication and insulin | 2.69 (1.35, 5.37) | 1.30 (0.67, 2.52) | 1 (reference) | 1.87 (0.97, 3.63) | 2.26 (0.99, 5.14) | 2.80 (1.43, 5.47) | 0.049 | |
No medication | 0.93 (0.30, 2.88) | 1.78 (0.81, 3.91) | 1 (reference) | 1.99 (0.99, 3.99) | 2.06 (0.57, 7.39) | 2.30 (0.92, 5.74) | 0.44 |